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Abstract
Shorter axial length observed in patients with primary angle closure glaucoma (PACG)
might be due to altered matrix metalloproteinase-9 (MMP9) activity resulting in ECM remod-
eling during eye growth and development. This study aimed to evaluate common variants in
MMP9 for association with PACG. Six tag SNPs ofMMP9 were genotyped in a Chinese
sample of 1,030 cases, including 572 PACG and 458 primary angle closure (PAC), and 499
controls. None of 6 SNPs were significantly associated with overall PAC/PACG (P > 0.07)
or with PAC/PACG subgroups (Pc > 0.18). Meta-analysis of two non-Chinese studies
revealed significant association between rs17576 and PACG (ORs = 0.56, P < 0.0001);
however, meta-analysis of our dataset with 4 Chinese datasets did not replicate this associ-
ation (ORs = 1.23, P = 0.29). Prior significant association for rs3918249 in one Caucasian
study (OR = 0.63, P = 0.006) was not replicated in meta-analysis of 3 Chinese studies
including this study (ORs = 0.91, P = 0.13). Significant heterogeneity between non-Chinese
and Chinese datasets precluded overall meta-analysis for rs17576 and rs3918249 (Q =
0.001 and 0.04 respectively). rs17577 was nominally associated with PACG in one Cauca-
sian study (OR = 1.71, P = 0.02), but not in 3 Chinese studies including our study (ORs =
1.20, P = 0.07). Overall meta-analysis revealed nominal association for rs17577 and PAC/
PACG (ORs = 1.26, Pc = 0.05). Meta-analysis did not show significant association between
the other SNPs and PAC/PACG (P > 0.47). The largest association study to date did not
find significant association betweenMMP9 and PAC/PACG in Chinese; meta-analysis with
other Chinese datasets did not produce significant association. In most instances combina-
tion with non-Chinese datasets was not possible except for one variant showing nominally
significant association. More work is needed to define the role ofMMP9 variants in PACG.
PLOSONE | DOI:10.1371/journal.pone.0157093 June 7, 2016 1 / 11
a11111
OPEN ACCESS
Citation: Chen X, Chen Y, Wiggs JL, Pasquale LR,
Sun X, Fan BJ (2016) Association of Matrix
Metalloproteinase-9 (MMP9) Variants with Primary
Angle Closure and Primary Angle Closure Glaucoma.
PLoS ONE 11(6): e0157093. doi:10.1371/journal.
pone.0157093
Editor: Ted S Acott, Casey Eye Institute, UNITED
STATES
Received: April 15, 2016
Accepted: May 24, 2016
Published: June 7, 2016
Copyright: © 2016 Chen et al. This is an open
access article distributed under the terms of the
Creative Commons Attribution License, which permits
unrestricted use, distribution, and reproduction in any
medium, provided the original author and source are
credited.
Data Availability Statement: All relevant data are
within the paper and its Supporting Information files.
Funding: This work was supported in part by the
Funds for International Cooperation and Exchange of
the National Natural Science Foundation of China
(81020108017) (XS) and National Natural Science
Foundation of China (81570887) (YC). A Harvard
Medical School Ophthalmology Distinguished Scholar
Award supports LRP. The funders had no role in
study design, data collection and analysis, decision to
publish, or preparation of the manuscript.
Introduction
Glaucoma is the leading cause of irreversible blindness worldwide, and is characterized by reti-
nal ganglion cell death which results in vision loss [1]. Primary open-angle glaucoma (POAG)
and primary angle closure glaucoma (PACG) are two major forms of glaucoma. PACG is char-
acterized by the apposition between the peripheral iris and trabecular meshwork, which causes
elevated intraocular pressure (IOP). It is estimated that PACG blinds more people than POAG
worldwide [2]. PACG is more prevalent in Asian populations, affecting approximately 0.75%
of adult Asians [3]. The prevalence of PACG is estimated to be 1.1% in the Chinese population
[3]. PACG is more common than previously thought in Caucasian populations. The prevalence
of PACG in those 40 years or more is 0.4% in European derived populations [4]. It is estimated
that 581,000 people in the U.S. are affected with PACG today, and this is projected to increase
by 18% within the next decade [4].
An unusually higher incidence of PACG among siblings of affected patients than the general
population suggests that genetic factors may play an important role in the development of
PACG [5,6]. However, the genetic basis of PACG is not well understood. Recently, two
genome-wide association studies identified four genetic loci for PACG, including ABCC5,
COL11A1, PLEKHA7 and an intergenic region between PCMTD1 and ST18 on chromosome
8q [7,8]. In addition, candidate gene studies have evaluated common variants in over 50 genes
for association with PACG and related phenotypes. A recent systematic review and meta-anal-
ysis highlighted the associations of 10 variants in 8 genes/loci with PACG and related pheno-
types, including COL11A1 (rs3753841),HGF (rs17427817 and rs5745718), HSP70 (rs1043
618),MFRP (rs2510143 and rs3814762),MMP9 (rs3918249), NOS3 (rs7830), PLEKHA7
(rs11024102) and PCMTD1-ST18 (rs1015213) [9]; however, at least 4 variants of 3 genes in
this study (i.e.,MFRP,MMP9 and NOS3) only showed nominal association and did not survive
the Bonferroni correction for multiple testing (all corrected P [Pc]> 0.05), and thus making
the associations of these genes with PACG inconclusive. The equivocal results in this meta-
analysis could be due to the relatively small sample sizes and limited statistical power (i.e., only
300–400 cases in total for each variant of the three genes). Further studies with larger samples
are required to clarify these associations.
In the present study, to help clarify the association betweenmatrix metalloproteinase-9
(MMP9) and PACG, we evaluated commonMMP9 variants for association with primary angle
closure (PAC) and PACG in a large Chinese Han sample. Moreover, we performed a meta-
analysis by including this Chinese dataset as well as published results from 5 Chinese studies
[10–14] and 2 non-Chinese studies [15,16].
Methods
Cases and controls
A total of 1,030 PAC or PACG cases (PAC/PACG) and 499 controls were recruited from the
Eye and Ear Nose Throat Hospital, Fudan University. The case group included 572 patients
with PACG and 458 patients with PAC. Among cases, 492 patients were acute PAC/PACG,
496 patients were chronic PAC/PACG, and 42 patients were not able to be classified into either
acute or chronic PAC/PACG. A complete eye examination was performed for each patient,
including examination of the anterior chamber with a slit-lamp, measurement of intraocular
pressure (IOP) by Goldmann applanation tonometry, and assessment of fundus photo. Gonio-
scopy, anterior chamber depth (ACD), axial length (AXL), and visual field were further exam-
ined if PAC or PACG was suspected. ACD, AXL and central corneal thickness (CCT) were
measured by A-scan ultrasound pachymetry. According to the definitions from the
Association ofMMP9with PAC/PACG
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International Society of Geographical and Epidemiological Ophthalmology (ISGEO) [17],
PACG was diagnosed based on the presence of glaucomatous optic neuropathy with a vertical
cup-disc ratio (VCDR) of 0.7 or greater, peripheral visual loss, an IOP> 21 mmHg, and the
presence of at least two quadrants of iridotrabecular contact in which the trabecular meshwork
was not visible on gonioscopy. PAC was diagnosed if trabecular obstruction by the peripheral
iris had occurred (IOP> 21 mmHg or peripheral anterior synechiae), but without glaucoma-
tous optic neuropathy. Acute PAC/PACG was defined as an episode with (1) a presenting
IOP> 28 mmHg; (2) at least two of the following symptoms: ocular or periocular pain, nausea,
vomiting, or an antecedent history of intermittent blurring of vision; and (3) at least three of
the following signs: conjunctival injection, corneal epithelial edema, mid-dilated nonreactive
pupil, or shallow anterior chamber [18]. Chronic PAC/PACG patients consisted of those with
no acute signs or symptoms, but met other criteria of PAC/PACG listed above [19]. Patients
with secondary angle closure glaucoma due to uveitis, trauma, neovascularization, or any other
optic nerve injury affecting either eye were excluded.
Control subjects had no evidence of PAC/PACG based on clinical exam, no family history
of glaucoma, no previous surgeries for glaucoma, and no other eye disorders besides senile
cataracts.
All the cases and controls were of self-reported Chinese Han ancestry. Demographic and
clinical features of the patients with PAC/PACG and controls were shown in Table 1.
This study followed the tenets of the Declaration of Helsinki and was approved by the ethi-
cal committee of Eye and Ear Nose Throat Hospital, Fudan University. Written informed con-
sent was obtained from all patients and controls after explanation of the nature and possible
consequences of the study.
Genotyping
We selected six tag SNPs that captured>95% of alleles at r2 greater than 0.8 across theMMP9
genomic region, including all exons, introns, the 5’- and 3’-UTR, and the 5-kb proximal pro-
moter region (Fig 1). Tag SNPs were selected according to the HapMap CHB+JPT data (ver-
sion 2, release 21) using Haploview (version 4.2) [20]. The minimumminor allele frequency
Table 1. Demographic and clinical features of cases and controls in this study.
PAC PACG Acute PAC/PACG Chronic PAC/PACG Overall PAC/PACG Controls
Number 458 572 492 496 1030b 499
Female (%) 74.7 57.3c 75.2 53.8c 65.1c 70.5
Age (year)a 57.9±11.1d 57.8±11.8d 58.0±11.5d 57.9±11.7d 57.8±11.5d 56.0±12.7
IOP at diagnosis (mm Hg) 28.7±15.7 29.3±13.3 31.2±16.7 27.5±11.6 29.0±14.4 N.A.
Maximum IOP (mm Hg) 31.4±16.2d 33.1±14.1d 34.3±17.0d 31.1±12.9d 32.4±15.1d 14.7±2.9
Vertical cup-disc ratio 0.43±0.12d 0.88±0.09d 0.61±0.24d 0.80±0.20d 0.69±0.24d 0.35±0.11
Anterior chamber depth (mm) 2.43±0.58 2.55±0.73 2.53±0.84 2.48±0.44 2.50±0.67 N.A.
Axial length (mm) 22.1±1.0d 22.3±1.0d 22.0±1.0d 22.4±1.0d 22.2±1.0d 24.2±1.7
Center cornea thickness (mm) 552.2±36.1d 536.9±34.0d 548.6±37.7d 538.8±33.3d 543.7±35.8d 528.8±33.6
All data were presented as (mean±standard deviation) except gender which was presented as percentage.
Abbreviations: IOP, intraocular pressure; N.A., not available; PAC, primary angle closure; PACG, primary angle closure glaucoma.
a Age at diagnosis for cases and age at enrollment for controls.
b Including 42 patients who were not able to be classiﬁed into either acute or chronic PAC/PACG.
c P < 0.05 compared to controls according to Chi-squared test.
d P < 0.05 compared to controls according to Mann-Whitney U test.
doi:10.1371/journal.pone.0157093.t001
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for checking SNPs was set to 0.1. Genotyping was performed by TaqMan assays (Applied Bio-
systems [ABI], Foster City, CA) according to the manufacturer’s instructions.
Statistical analysis
The analysis of CCT, ACD and AXL was performed using the average measurements from
both eyes. IOP and VCDR were analyzed using the eye with greater values. Chi-squared test
was used to compare the difference in sex between cases and controls. Mann-Whitney U test
was used to compare the differences in age, IOP, VCDR, ACD, AXL and CCT between cases
and controls.
The linkage disequilibrium (LD) plot was generated using Haploview (version 4.2) [20],
where squared Pearson correlation coefficient (r2) was used to measure LD. Hardy-Weinberg
equilibrium was assessed by the chi-squared test. The association analysis was performed using
PLINK (version 1.07) [21] for overall PAC/PACG, the subgroups (PAC, PACG, acute PAC/
PACG and chronic PAC/PACG), and the subphenotypes (age at diagnosis, IOP at diagnosis,
maximum IOP, VCDR, ACD, AXL and CCT). Logistic or linear regression was used to adjust
for age and sex in the association analysis. Multiple comparisons were corrected for the num-
ber of SNPs for each analysis using the Bonferroni method.
As described in detail previously [22], haplotype analysis was performed with the standard
Expectation-Maximization algorithm and the chi-squared test. P values were obtained from
the haplotype-specific test and the omnibus test. The odds ratio (OR) and 95% confidence
interval (CI) were calculated for each of individual haplotypes.
Fig 1. Linkage disequilibrium plot of the 6 tag SNPs aroundMMP9 in the Chinese dataset of this
study. The numbers in the diamond indicate r2; black represented r2 = 1, shades of grey indicated 0< r2 <1,
and white referred to r2 = 0. Chromosomal positions were based on NCBI build 36.3 (National Center for
Biotechnology Information, Bethesda, MD).
doi:10.1371/journal.pone.0157093.g001
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Meta-analysis was performed using the Mantel-Haenszel method, assuming fixed or ran-
dom effects based on the heterogeneity test results. The heterogeneity between datasets was
evaluated using the heterogeneity index (I2) and the Cochran’s Q statistic [23]. The forest plot
was generated using Inkscape (Release 0.91, The Inkscape Team, 2015, www.inkscape.org)
based on the output from the Review Manager software (RevMan, version 5.3; Copenhagen:
The Nordic Cochrane Centre, The Cochrane Collaboration, 2014).
Power analysis for association ofMMP9 SNPs with PAC/PACG was performed using the
Genetic Power Calculator [24]. The disease prevalence was set as 0.4% for the non-Chinese
datasets [4] and 1.1% for the Chinese datasets [3]. The risk allele frequency was set to the same
as the marker allele frequency, with 0.38 and 0.34 for the non-Chinese and Chinese datasets
based on the allele frequencies of rs17576 in the 1000 Genomes Project [25]. Linkage disequi-
librium between the marker and the risk allele was set at D’ = 1.0. The genotypic relative risks
for heterozygous (Aa)/high risk homozygous (AA) genotypes were set as 1.78/3.17 and 1.23/
1.51 respectively for the non-Chinese and Chinese datasets based on the results of meta-analy-
ses for rs17576, assuming an additive risk model [24].
Power analysis for association ofMMP9 SNPs with subphenotypes in PAC/PACG cases
was performed using R scripts [26], assuming a linear model. The phenotypic variance
explained by additive effects at the marker of interest was set as 1%-5%.
Results
All 6 tag SNPs followed Hardy-Weinberg equilibrium in both case and control groups
(P> 0.1). None of the 6MMP9 tag SNPs were significantly associated with overall PAC/PACG
(age and sex adjusted P> 0.07; Table 2) or with the subgroups (age and sex adjusted P> 0.03
and 0.08 for PAC and PACG respectively, Table 2; age and sex adjusted P> 0.04 and 0.08 for
acute and chronic PAC/PACG respectively, S1 Table; all Pc> 0.18 after correction for multiple
testing).
Haplotype analysis of 6 tag SNPs did not find significant association ofMMP9 with overall
PAC/PACG (P> 0.11; S2 Table), or the subgroups (P> 0.05 and 0.16 for PAC and PACG
respectively, S2 Table; P> 0.09 and 0.08 for acute and chronic PAC/PACG respectively; S3
Table).
Analysis of subphenotypes in the PAC/PACG cases did not reveal significant association of
MMP9 SNPs with age at diagnosis, IOP at diagnosis, maximum IOP, VCDR, ACD, AXL and
CCT (age and sex adjusted P> 0.15; S4 and S5 Tables).
Table 2. Single-SNP association analysis ofMMP9 tag SNPs with PACG in this study.
MAF PAC PACG Overall PAC/PACG
SNP MA PAC PACG Overall PAC/PACG Controls OR (95%CI) P OR (95%CI) P OR (95%CI) P
rs4810482 T 0.27 0.29 0.28 0.31 0.80 (0.65–0.98) 0.03 0.94 (0.78–1.14) 0.51 0.86 (0.73–1.02) 0.11
rs3918249 T 0.27 0.29 0.28 0.31 0.81 (0.66–0.99) 0.04 0.94 (0.78–1.14) 0.53 0.87 (0.74–1.03) 0.14
rs17576 A 0.28 0.30 0.29 0.31 0.85 (0.70–1.04) 0.12 0.96 (0.80–1.16) 0.68 0.90 (0.76–1.06) 0.27
rs3918254 T 0.19 0.18 0.19 0.16 1.24 (0.98–1.57) 0.08 1.16 (0.93–1.45) 0.19 1.21 (0.99–1.48) 0.08
rs3787268 A 0.40 0.38 0.39 0.41 0.96 (0.79–1.15) 0.65 0.86 (0.72–1.02) 0.08 0.90 (0.77–1.05) 0.17
rs17577 A 0.15 0.15 0.15 0.12 1.22 (0.93–1.60) 0.16 1.23 (0.95–1.59) 0.11 1.23 (0.98–1.55) 0.07
Abbreviation: MA, minor allele; MAF, minor allele frequency; PAC, primary angle closure; PACG, primary angle closure glaucoma. The Bonferroni
corrected signiﬁcance level was set as 0.008 (0.05/6).
doi:10.1371/journal.pone.0157093.t002
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Meta-analysis of the published data from two non-Chinese populations [15,16] showed sig-
nificant association between rs17576 and PACG (summary OR [ORs] = 0.56, 95% CI: 0.42–
0.74, P< 0.0001; Fig 2). Meta-analysis of our Chinese data with the published data from 4 Chi-
nese populations [10–13] did not find significant association of rs17576 with PAC/PACG
(ORs = 1.23, 95% CI: 0.83–1.82, P = 0.29; Fig 2). Significant heterogeneity between the non-
Chinese and Chinese populations precluded an overall meta-analysis for rs17576 (Q = 0.001,
I2 = 90%; Fig 2). Significant association was reported for rs3918249 in one study of the Cauca-
sian population (OR = 0.63, 95% CI: 0.45–0.88, P = 0.006; Fig 3), while no significant associa-
tion was found for rs3918249 in the meta-analysis of 3 Chinese studies that included this work
(ORs = 0.91, 95%CI: 0.80–1.03, P = 0.13; Fig 3). Significant heterogeneity was observed
Fig 2. Meta-analysis with prior studies of the association between rs17576 and PAC/PACG.Odds ratio was calculated per each increase
in minor allele A. The summary odds ratio was 0.56 (95%CI: 0.42–0.74) for the non-Chinese populations and 1.23 (95% CI: 0.83–1.82) for the
Chinese populations. Significant heterogeneity between the non-Chinese and Chinese populations precluded an overall meta-analysis for
rs17576 (Q = 0.001, I2 = 90%). The Bonferroni corrected significance level was set as 0.01 (0.05/5).
doi:10.1371/journal.pone.0157093.g002
Fig 3. Meta-analysis with prior studies of the association between rs3918249 and PAC/PACG.Odds ratio was calculated per each
increase in minor allele T. The summary odds ratio was 0.63 (95%CI: 0.45–0.88) for the Caucasian population and 0.91 (95%CI: 0.80–1.03) for
the Chinese populations. Significant heterogeneity between the Caucasian and Chinese populations precluded an overall meta-analysis for
rs3918249 (Q = 0.04, I2 = 75%). The Bonferroni corrected significance level was set as 0.01 (0.05/5).
doi:10.1371/journal.pone.0157093.g003
Association ofMMP9with PAC/PACG
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between the Caucasian and Chinese studies (Q = 0.04, I2 = 75%; Fig 3), making it impossible to
include the Caucasian data in the meta-analysis of rs3918249. Similarly, rs17577 was nominally
associated with PACG in one Caucasian study (OR = 1.71, 95% CI: 1.09–2.67, P = 0.02; Fig 4),
but not in three Chinese studies that included our data (ORs = 1.20, 95% CI: 0.99–1.45,
P = 0.07; Fig 4). Since no significant heterogeneity was found between the Caucasian and Chi-
nese studies (Q = 0.15, I2 = 52%; Fig 4), an overall meta-analysis of the combined Caucasian
and Chinese populations showed nominal association between rs17577 and PAC/PACG
(ORs = 1.26, 95%CI: 1.06–1.50, P = 0.01, Pc = 0.05; Fig 4). Meta-analysis did not show significant
association between rs3918254 and PAC/PACG (ORs = 1.01, 95%CI: 0.68–1.50, P = 0.95; S1 Fig)
or between rs3787268 and PAC/PACG (ORs = 0.95, 95%CI: 0.84–1.08, P = 0.47; S2 Fig).
Discussion
In the present study, we evaluated tag SNPs that captured>95% of genetic variation in the
MMP9 gene region as well as the proximal 5-kb promoter for association with PACG in a large
Chinese case-control dataset. No significant association was found between common SNPs or
haplotypes ofMMP9 and PAC/PACG in this Chinese sample (Table 2, S2 Table). MMP9 is a
member of a large family of endopeptidases which are involved in the remodeling and degrada-
tion of extracellular matrix (ECM) [27]. Functional variants have been identified in theMMP9
gene. It is hypothesized that shorter axial length observed in patients with PACGmight be due
to a change in the MMP9 activity resulting in ECM remodeling during eye growth and devel-
opment [10].
A coding variant rs17576 in exon 6 ofMMP9 leads to the substitution of arginine by gluta-
mine, which might change the enzyme activity of MMP9 [28]. Previous studies have identified
significant associations between rs17576 and PACG in one Australian Caucasian population
[15], one Pakistani population [16] and one Chinese population [10]. However, three subse-
quent studies on Chinese patients did not replicate this association [11–13]. Our study also
failed to find an association between rs17576 and PAC/PACG in a larger Chinese sample
Fig 4. Meta-analysis with prior studies of the association between rs17577 and PAC/PACG.Odds ratio was calculated per each increase in
minor allele A. The summary odds ratio was 1.71 (95% CI: 1.09–2.67) for the Caucasian population, 1.20 (95% CI: 0.99–1.45) for the Chinese
populations, and 1.26 (95%CI: 1.06–1.50) for the combined Caucasian + Chinese populations, respectively. The odds ratios between the
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(Table 2, S2 Table). To further evaluate this association, we performed a meta-analysis using
our genotype data for the Chinese dataset as well as published data for the Chinese and non-
Chinese datasets. Our meta-analysis revealed significant association between rs17576 and
PACG in the non-Chinese populations but not in the Chinese populations (Fig 2). Significant
heterogeneity between the non-Chinese and Chinese datasets was observed for rs17576 pre-
cluding an overall meta-analysis for this SNP (Fig 2). Notably, the risk allele is “G” in the non-
Chinese populations, which is different from that in the Chinese populations (i.e., “A”). Such
“flip-flop” associations may be due to population-specific effects [29], which have been well
documented in genetic association studies such as the association of LOXL1 with exfoliation
syndrome [30–32]. Alternatively, the limited sample sizes in the non-Chinese populations
might have biased the observed associations between rs17576 and PACG. Further analyses
using larger samples or other populations such as Africans will be helpful to clarify this issue.
The findings of significant association between commonMMP9 variants and PACG in the
non-Chinese populations but not in the Chinese populations were further supported by the
results of additional two SNPs inMMP9, rs3918249 (Fig 3) and rs17577 (Fig 4). Both
rs3918249 and rs17577 were reported to be significantly associated with PACG in a Caucasian
study [15]. However, meta-analyses of our data with the published data from the Chinese pop-
ulations [10,13,14] did not identify significant association of rs3918249 and rs17577 with PAC/
PACG (Figs 3 and 4). An overall meta-analysis of the combined Caucasian and Chinese popu-
lations revealed nominal association for rs17577 (Pc = 0.05; Fig 4). Our meta-analysis of the
combined Caucasian and Chinese datasets did not find significant association of rs3918254
and rs3787268 with PAC/PACG (S1 and S2 Figs), suggesting that these SNPs are not likely to
contribute to the disease. Alternatively, the relatively low frequency of the risk allele for
rs3918254 might have prevented us from detecting the association due to insufficient statistical
power, particularly in the Caucasian population.
Polymorphisms in the promoter region ofMMP9 have been reported to affect the gene tran-
scription [16]. The promoter region has been poorly investigated in previous association stud-
ies forMMP9 and PACG. Only one SNP, rs3918242, located at 1,562 base pairs upstream of
theMMP9 start codon, was investigated in the Pakistani study [16], while promoter region
SNPs were not included in other studies [10–15].The present study is the first time that an
association between theMMP9 promoter region and PAC/PACG has been evaluated using tag
SNPs. We did not identify significant association between theMMP9 promoter region and
PAC/PACG in the Chinese dataset (Table 2), consistent with the results from the Pakistani
study [16]. These results suggest that theMMP9 promoter may not contribute to PACG risk,
although further studies using larger datasets are required to confirm these findings.
A major limitation of previousMMP9 association studies is the relatively small sample sizes
(no more than 300 in either case or control group). In this study, we enrolled a larger sample
(1,030 cases and 499 controls), making it the largest study onMMP9 common variants and
PAC/PACG to date. Our meta-analysis of rs17576 suggests that genetic effects ofMMP9 vari-
ants are likely to be modest and on the order of 1.78/3.17 and 1.23/1.51 for Aa/AA in the non-
Chinese and Chinese datasets respectively (Fig 2). We estimated that we had 98% of power in
all the non-Chinese datasets (189 cases and 406 controls), 48% of power in our Chinese dataset
(1,030 cases and 499 controls), and 88% of power in all the Chinese datasets (1,768 cases and
1,179 controls) to detect this modest genetic effect [24]. Notably, the GWAS in the Chinese
populations by Vithana et al. (1,854 cases and 9,608 controls in the discovery dataset) had only
63% power to detect the association between rs17576 and PACG, and this may explain why
this study did not identify significant association [8].
Our analysis of subphenotypes in the PAC/PACG cases did not find significant association
ofMMP9 variants with age at diagnosis, IOP at diagnosis, maximum IOP, VCDR, ACD, AXL
Association ofMMP9with PAC/PACG
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and CCT (S4 and S5 Tables), suggesting that common variants inMMP9might not contribute
to the disease severity. We estimated that we had 71.6%-99.9% of power to detect the genetic
effect ofMMP9 SNPs on these quantitative subphenotypes, assuming the phenotypic variance
explained by additive effects at the marker of interest as 1%-5%.
Conclusions
We have evaluated common variants inMMP9 as genetic risk factors for PAC/PACG.
This is the largest association study onMMP9 and PAC/PACG to date. Prior results suggest
that commonMMP9 variants may contribute to the modest risk for PACG in the non-Chi-
nese population but our analysis suggests this not the case in the Chinese population. Addi-
tional studies using larger datasets will be necessary to confirm these population-specific
findings.
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